

Thursday, 22 October 2026

14.30 – 16.30 Case Reports

Chairs: **A. Tzioufas - A. Goules**

16.30 – 17.45 Seronegative Arthritis

Chairs: **G. Katsifis - S. Sougioultzis**

Pathogenetic mechanisms of seronegative arthritis

G. Katsifis

Clinical evaluation and recommendations

G. Fragoulis

Treatment of patients with seronegative arthritis

Ch. Papagoras

17.45 – 18.00 Coffee break

18.00 – 18.30 Rheuma-Hematology

Chairs: **S. Sougioultzis - S. Gazi**

The clinical significance of monoclonal gammopathy

E. Terpos

18.30 – 19.00 Satellite (2)

19.00 – 20.00 Introduction | Opening Lecture

Chairs: **A. Tzioufas - S. Sougioultzis**

H.M. Moutsopoulos

Advances in pathophysiology and emerging therapeutic trends in interstitial lung disease associated with connective tissue diseases

O. Distler

20.00 – 20.30 Satellite (3)

Friday, 23 October 2026

09.30 – 10.15 Antiphospholipid Syndrome

Chairs: **L. Chatzis**

Current pathogenetic considerations and treatment of catastrophic antiphospholipid syndrome
R. Cervera

10.15 – 11.00 ANCA-associated Vasculitides

Chairs: **C. Salvarani**

Comorbidities in ANCA-associated vasculitides
D. Vassilopoulos

11.00 – 11.30 Coffee Break

11.30 – 12.15 Keynote Lecture

Chairs: **A. Tzioufas – A. Goules**

Recent advances in pathogenesis of rheumatoid arthritis
C. Pitzalis

12.15 – 13.15 Myositis/ Scleroderma

Chairs: **C. Mavragani – A. Georgountzos**

Recent advances in pathogenesis and treatment of inflammatory muscular diseases
C. Mavragani

Recent advances in pathogenesis and treatment of systemic sclerosis
S. Panopoulos

13.15 – 14.15 Light Lunch Break

14.15 – 14.45 Keynote Lecture

Chairs: **G. Dimopoulos – A. Goules**

Advances in the pathogenetic mechanisms of EGPA and current therapeutic considerations
B. Terrier

14.45 – 15.15 Satellite Lecture – Amgen

15.15 – 16.45 Operating Mechanisms in Chronic Inflammatory Diseases

Chairs: **E. Andreakos**

Molecular signatures of monocytes in health and disease

I. Mitroulis

New pathogenetic aspects in immunothrombosis

K. Kampas

The role of IL-1 β in giant cell arteritis

S. Croci

16.45 - 17.00 Coffee Break

17.00 - 18.00 Rheumatoid Arthritis

Chairs: **A. Drosos**

Comorbidities in rheumatoid arthritis

G. Kitas

Seronegative vs Seropositive Rheumatoid arthritis; Phenotypic and endotypic differences & similarities

P. Voulgari

18.00 - 18.30 Sjögren's Syndrome

Immunopathology of Sjögren's disease

A. Goules

L. Chatzis

18.30 – 19.00 Satellite Lecture – Thea

19.00 - 19.45 Keynote Lecture: Current and Future Therapeutic Aspects

Chairs: **A. Tzioufas - O. Distler**

Current therapeutic strategies and future perspectives in large vessel vasculitides

C. Salvarani

19.45 - 20.15 Systemic Lupus Erythematosus

Chairs: **R. Cervera**

Therapeutic interventions in systemic lupus erythematosus

N. Liossis

20.15 – 20.45 Imaging

Chairs: **A. Chatziioannou**

PET-CT in vascular inflammation

C. Anagnostopoulos

Saturday, 24 October 2026

09.30 – 10.30 Disease chronicity and tissue damage

Chairs: **A. Goules - L. Chatzis**

Immunopathology in Sjögren's disease: emerging concepts

S. Verstappen

Tissue damage in obesity and Metabolic dysfunction-associated steatotic liver disease

A. Chatzigeorgiou

10.30 – 10.45 Coffee Break

10.45 – 13.00 Immunity to infections

Chairs: **E. Andreakos - G. Chamilos**

Immunity to fungal pathogens (TBC)

G. Chamilos

New advances in type III interferons

V. Andreakos

Residual chronic inflammation in Systemic Autoimmune Diseases: The example of temporal arteritis

A. Tzioufas

13.00 – 14.00 Light Lunch Break

14.00 – 16.00 Work in progress (12min talks)

Phenotypic and functional analysis of neutrophils in chronic respiratory disease – **A. Deligianni**

D. Palamidas

P. Palla

Prognostic artificial intelligence models for histopathologic risk stratification of lymphoma and systemic complications in Sjögren Disease – **K. Panagiotopoulos**

P. Panagopoulos

Lipid Mediators in Health and Disease – **M. Papadaki**

A. Piperakis

Persistence of Neutrophil Extracellular Traps, Senescent Cells and Exhausted T Cells in sequential temporal artery biopsies of giant cell arteritis patients treated with Tocilizumab – **Ch. Spyropoulos**

N. Vlachogiannis

16.00 – 16.30

Chairs: **A. Tzioufas - A. Goules**

Clinical and Molecular Aspects of Type I Interferon Pathway in SLE

G. Bertsias

16.30 – 17.30 Closing